Skip to content
← Index board

Health Optimization Index

Melanotan I (Afamelanotide)

Nick’s assessment
Promising
Research evidence
B, good evidence
Attention
16.7 / 100▲ Rising this week
6.2/ 10

BioHarmony score

Melanotan I is most defensible for photoprotection in EPP and planned UV exposure, with Langendonk 2015 reporting 69.4 vs 40.8 hours of pain-free sun exposure in the US trial. The wellness case is narrower than the prescription afamelanotide evidence.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

Melanotan I is worth trying when the goal is real photoprotection or pigment support and you can verify your source, not as a casual tanning shortcut. The 6.0–6.5/10 score reflects a compound with strong evidence in a narrow lane (erythropoietic protoporphyria), genuine benefit for very fair-skinned people who burn easily, and an intrinsic safety profile that is manageable with skin monitoring. The catch is that the approved drug and the injectable vials sold online are very different products in everything except the molecule itself.

✅ Best for: Adults with EPP under specialist care; very fair-skinned people who burn despite disciplined sun habits; vitiligo patients considering combination phototherapy with a dermatologist; and experienced peptide users who can verify their sourcing and commit to regular skin checks. It is also the better melanotan when you want pigment and UV tolerance without the appetite and libido effects of Melanotan II.

❌ Avoid if: You have a suspicious or changing mole, an active melanoma workup, dysplastic-nevus syndrome without dermatology oversight, pregnancy or lactation without clinician sign-off, severe liver or kidney impairment, or any unwillingness to get skin checks. Also avoid injectable vials that lack sterility documentation, identity testing, or a clear guarantee they are not actually Melanotan II.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on Melanotan I (Afamelanotide)
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 21, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.